Form 8-K - Current report:
SEC Accession No. 0001628280-25-038570
Filing Date
2025-08-07
Accepted
2025-08-07 07:02:06
Documents
15
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20250807.htm   iXBRL 8-K 28383
2 EX-99.1 ex-9912q2025earningsrelease.htm EX-99.1 120669
7 GRAPHIC avalo-logoxblk1a.jpg GRAPHIC 99614
  Complete submission text file 0001628280-25-038570.txt   446199

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250807.xsd EX-101.SCH 2104
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20250807_def.xml EX-101.DEF 15013
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250807_lab.xml EX-101.LAB 25388
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250807_pre.xml EX-101.PRE 15588
17 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250807_htm.xml XML 3556
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 251191510
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)